Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Episodic ataxia type 3 (EA3) is a very rare form of Hereditary episodic ataxia characterized by vestibular ataxia, vertigo, tinnitus, and interictal myokymia.
Features include: Myokymia, Diplopia, Vomiting, and Vertigo and 5 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 2 | Vomiting, Nausea |
Ears |
Biomarker and diagnostic research for episodic ataxia type 3 has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
115 publications have been identified in PubMed for episodic ataxia type 3. Kisho has analyzed 71 by research type. Research spans Review / Meta-Analysis (45%), Case Report / Case Series (18%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 32 |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:53 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Vertigo, Tinnitus |
Brain and nerves | 2 | Episodic ataxia, Headache |
Eyes | 1 | Diplopia |
Muscles | 1 | Muscle weakness |
Patient case studies | 13 | 18% |
Disease patterns and progression | 13 | 18% |
Clinical study results | 6 | 8% |
Testing and diagnosis research | 3 | 4% |
Laboratory research | 3 | 4% |
Other research | 1 | 1% |
Shah RJ (2026). [PMID: 31082085](https://pubmed.ncbi.nlm.nih.gov/31082085/). *Unknown Journal*. [Clinical Trial Publication]
Chinigioli M (2026). [PMID: 41370964](https://pubmed.ncbi.nlm.nih.gov/41370964/). *Eur J Paediatr Neurol*. [Diagnostic / Biomarker]
Patel PR (2026). [PMID: 33232046](https://pubmed.ncbi.nlm.nih.gov/33232046/). *Unknown Journal*. [Clinical Trial Publication]
Kim HJ (2026). [PMID: 41781521](https://pubmed.ncbi.nlm.nih.gov/41781521/). *J Neurol*. [Diagnostic / Biomarker]
Palmeri S (2026). [PMID: 41365842](https://pubmed.ncbi.nlm.nih.gov/41365842/). *Rheumatology (Oxford)*. [Case Report / Case Series]
Mars JA (2026). [PMID: 36256781](https://pubmed.ncbi.nlm.nih.gov/36256781/). *Unknown Journal*. [Epidemiology / Natural History]
Greenberg E (2026). [PMID: 41633751](https://pubmed.ncbi.nlm.nih.gov/41633751/). *Handb Clin Neurol*. [Review / Meta-Analysis]
Shah F (2026). [PMID: 33760515](https://pubmed.ncbi.nlm.nih.gov/33760515/). *Unknown Journal*. [Clinical Trial Publication]
Park S (2026). [PMID: 42073066](https://pubmed.ncbi.nlm.nih.gov/42073066/). *Children (Basel)*. [Case Report / Case Series]
Greene KA (2025). [PMID: 39133210](https://pubmed.ncbi.nlm.nih.gov/39133210/). *Neurogastroenterol Motil*. [Review / Meta-Analysis]